Can a lupus drug protect lungs in connective tissue disease?

NCT ID NCT06716606

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to several years. Researchers will track side effects and measure how well the drug slows lung function decline and improves daily life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belimumab
What this could lead to: If successful, belimumab could offer a long-term treatment option to slow lung function decline and improve quality of life in people with connective tissue disease-related lung scarring.
What could go wrong: This is an open-label extension study, meaning everyone gets the drug and there is no placebo group, so results may be less definitive. Long-term safety is still being evaluated, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

connective tissue disorder diffuse scleroderma interstitial lung disease pulmonary systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONNECTIVE TISSUE DISEASES

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site
RECRUITING

Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
GSK Investigational Site
RECRUITING

Ciudad Autonoma de Buenos Aire, 1425, Argentina
GSK Investigational Site
RECRUITING

Beijing, 100020, China
GSK Investigational Site
RECRUITING

Zhuzhou, 412007, China
GSK Investigational Site
RECRUITING

Larissa, 41110, Greece
GSK Investigational Site
RECRUITING

Hokkaido, 060-8648, Japan
GSK Investigational Site
RECRUITING

Tokyo, 113-8603, Japan
GSK Investigational Site
RECRUITING

Yongsan-Ku Seoul, South Korea
GSK Investigational Site
RECRUITING

London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.